Alpha-synuclein is a protein that is abundantly
found in the brain. The minimal amount of alpha-synuclein is also found in the
heart and other tissues. The protein is prominently found at the tips of the
nerve cells. It helps in the maintaining supply of the synaptic vesicle in
presynaptic terminals.
In addition,
the alpha-synuclein protein also helps in release of dopamine. The protein
comprised of 140 amino acids and is encoded by Synuclein Alpha (SNCA) gene. It
produced mostly in hippocampus, neocortex, substantia nigra, and cerebellum.
However, the actual function of alpha-synuclein is still completely unknown.
However, the pathophysiology of Parkinson’s disease is associated with the
accumulation of alpha-synuclein protein which forms Lewy bodies.
Request to Get the Sample Pages at:
F.
Hoffmann-La Roche Ltd. is in the process of developing RG7935 as a monoclonal
antibody targeting alpha-synuclein, for the treatment of Parkinson’s disease.
AC Immune SA is in the process of developing morphomer α-syn as an
alpha-synuclein inhibitor for the treatment of Parkinson’s disease. Neuropore
Therapies Inc. is also developing a drug candidate that targets alpha-synuclein,
for the treatment of Parkinson’s disease and multiple system atrophy.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.
No comments:
Post a Comment